All In Biotech

BLA 020563 · Lilly

Humalog Kwikpen

Insulin Lispro Recombinant · Injection · Insulin Analog

Novel

Last checked: Nov 20, 2026Latest source record: May 7, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1996

Jun 14, 1996

Approved uses

9

Original approval plus efficacy supplements

Registered trials

15

0 Phase 3, 0 recruiting

FAERS reports

129,052

60,658 serious, 5,766 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 18, 2026.

Insulin Lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Insulin Lispro is a rapid acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. ( 1 )

Mechanism: Regulation of glucose metabolism is the primary activity of insulins and insulin analogs, including insulin lispro. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis, and enhance protein synthesis.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 14, 2012 Supplement 123 · Efficacy LetterLabel
  • May 18, 2011 Supplement 105 · Efficacy LabelLetter
  • Jun 2, 2004 Supplement 24 · Efficacy LabelLetter
  • Oct 25, 2002 Supplement 35 · Efficacy
  • Apr 4, 2000 Supplement 10 · Efficacy LabelLetter
  • Apr 4, 2000 Supplement 13 · Efficacy LetterLabel
  • Apr 4, 2000 Supplement 11 · Efficacy LetterLabel
  • Apr 4, 2000 Supplement 12 · Efficacy LetterLabel
  • Jun 14, 1996 Original approval · Type 1 - New Molecular Entity Review
5 products under this application
  • HUMALOG KWIKPEN · INSULIN LISPRO RECOMBINANT 200UNITS/ML · INJECTABLE, INJECTION · Prescription
  • HUMALOG PEN · INSULIN LISPRO RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Discontinued
  • HUMALOG TEMPO PEN · INSULIN LISPRO RECOMBINANT 100UNITS/ML · INJECTABLE, INJECTION · Prescription
  • HUMALOG KWIKPEN · INSULIN LISPRO RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Prescription
  • HUMALOG · INSULIN LISPRO RECOMBINANT 100 UNITS/ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Insulin Lispro Recombinant" as an intervention, any sponsor and status, largest first.

All 15 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • blood glucose increased36,329
  • incorrect dose administered8,658
  • blood glucose decreased8,320
  • drug ineffective7,715
  • visual impairment5,049
  • nausea4,797
  • malaise3,739
  • fatigue3,696
  • hypoglycaemia3,671
  • fall3,343
  • drug dose omission3,323
  • diarrhoea3,188

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,189
20051,265
20061,680
20071,554
20081,463
20091,792
20101,841
20112,034
20122,107
20131,732
20144,580
201524,791
20168,487
20179,234
20188,994
20198,984
20209,182
20217,793
20226,793
20235,902
20245,555
20258,089
20264,011

Recalls

2 FDA enforcement reports for this application.

  • Mar 12, 2024 · Class II · Completed

    CGMP Deviations

  • Apr 5, 2022 · Class I · Completed

    TEMPERATURE ABUSE: Products were exposed to temperatures outside of the products labeled storage conditions due to inclement weather.

Shortages

FDA's drug shortage list.

  • To Be Discontinued · updated Sep 1, 2026

    Insulin Lispro Junior KwikPen, Injection, 100 [iU]/1 mL (NDC 0002-7752-05). A business decision was made to discontinue manufacture of the drug. Distribution projected to end June 2027. If patients or prescribers have...

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Humalog (Insulin Lispro)

2024 spending

$98.4M

Beneficiaries

149,275

511,120 claims

Per beneficiary

$659

$6.18 per unit

View as table
YearSpending
2020$449,251,292
2021$435,057,237
2022$440,789,067
2023$458,058,582
2024$98,416,547

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 3 on PubMed

Sponsor: Eli Lilly · Also marketed as Humalog Pen, Humalog Tempo Pen, Humalog

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.